Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$83.04 USD

83.04
5,653,121

+0.83 (1.01%)

Updated Sep 26, 2024 04:00 PM ET

Pre-Market: $83.25 +0.21 (0.25%) 9:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Is a Beat in Store for Vertex (VRTX) This Earnings Season?

Vertex (VRTX) is expected to beat estimates when it reports its Q1 earnings on Apr 26.

    Is a Beat in Store for Alexion (ALXN) This Earnings Season?

    Impressive sales of Alexion's blockbuster drug, Soliris might lead the company toward an earnings beat in Q1.

      Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings?

      Bristol-Myers (BMY) is scheduled to report Q1 earnings on Apr 26.

        The Zacks Analyst Blog Highlights: IBM, McDonald's, Gilead, Phillips 66 and Lam Research

        The Zacks Analyst Blog Highlights: IBM, McDonald's, Gilead, Phillips 66 and Lam Research

          Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics

          The biotech space was a witness to a series of events. while share price of several stocks moved up, a few fell substantially.

            Gilead (GILD) Presents Encouraging Data on NASH Therapies

            Gilead Sciences (GILD) announces encouraging data from a proof-of-concept study on experimental combination NASH therapies at The International Liver Congress 2018 in Paris.

              Bristol-Myers Collaborates With Harvard Fibrosis Network

              Bristol-Myers (BMY) announces a research collaboration agreement with Harvard Fibrosis Network to discover and develop potential new therapies for fibrotic diseases, including fibrosis of the liver and heart.

                Alexion (ALXN) to Acquire Wilson Therapeutics for $855M

                Alexion (ALXN) announces that the company will acquire Sweden-based Wilson Therapeutics for $855 million, the latest company to join the ongoing acquisitions spree in the biotech sector.

                  Pfizer Inks New CAR-T Deal, In Talks With P&G for Unit Sale

                  Pfizer (PFE) out-licenses CAR-T assets to Allogene Therapeutics to expedite development. CNBC report says Pfizer in talks with P&G regarding sale of its Consumer Healthcare unit.

                    The Zacks Analyst Blog Highlights: United Technologies, Medtronic, Gilead, Hewlett Packard and Yum! Brands

                    The Zacks Analyst Blog Highlights: United Technologies, Medtronic, Gilead, Hewlett Packard and Yum! Brands

                      Celgene Loses 17.8% in 3 Months: Time to Reshuffle Portfolio?

                      Things have not been going Celgene's (CELG) way as the company has suffered a series of setbacks. The stock has lost 17.8% in the last three months.

                        3 Sell-Rated Drug Stocks Investors Should Avoid for Now

                        Despite a fairly upbeat performance of the pharma and biotech sector, caution has to be exercised before choosing a stock for investment as a few drug companies are struggling to revive business.

                          Is Gilead Sciences (GILD) a Great Stock for Value Investors?

                          Let's see if Gilead Sciences Inc. (GILD) stock is a good choice for value-oriented investors right now from multiple angles.

                            Kevin Cook headshot

                            Bull of the Day: Regeneron (REGN)

                            Key pharma franchises in a bustling pipeline have shares looking attractive again at 17X and 15% EPS growth

                              3 Biotech Stocks With Rising Earnings Estimates Post Q4

                              The biotech industry performed reasonably well in Q4. Hence, it is a good idea to select stocks from the sector which saw positive estimate revisions post Q4 earnings release.

                                Gilead Sciences (GILD) Down 3.4% Since Earnings Report: Can It Rebound?

                                Gilead Sciences (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                  Biotech Stock Round Up: Regeneron Submits sBLA, Biogen to Withdraw Zinbryta

                                  The biotech sector was in focus last week with these stories - FDA's acceptance of Regeneron's Dupixent's application for asthma, Biogen and partner AbbVie's decision to withdraw multiple sclerosis drug among others.

                                    Gilead Announces Positive Data on New HIV Therapy Biktarvy

                                    Gilead (GILD) announces encouraging data from a phase III study, on its new HIV therapy, Biktarvy, at the 2018 Conference on Retroviruses and Opportunistic Infections in Boston.

                                      Biotech ETFs Head to Head: XBI vs. IBB.

                                      Head-to-head comparison of two Biotech ETFs, XBI and IBB.

                                        The Zacks Analyst Blog Highlights: Gilead, BNY Mellon, State Street, Alliant Energy and Dillard's

                                        The Zacks Analyst Blog Highlights: Gilead, BNY Mellon, State Street, Alliant Energy and Dillard's

                                          Biotech Stock Round Up: Celgene Suffers Setback, Gilead Teams Up with Sangamo

                                          The major news in the biotech sector in the last five trading sessions include the FDA's refusal to file letter for Celgene Corporation's (CELG) ozanimod while Gilead Sciences, Inc.'s (GILD) announced an agreement with Sangamo Therapeutics.

                                            Mark Vickery headshot

                                            Top Analyst Reports for Gilead, BNY Mellon & State Street

                                            Today's Research Daily features new research reports on 12 major stocks, including Gilead (GILD), BNY Mellon (BK) and State Street (STT).

                                              Intercept (ICPT) Q4 Earnings & Sales Lag on Dull Ocaliva

                                              Intercept (ICPT) missed on both earnings and revenues in the fourth quarter as Ocaliva sales were drab due to safety issues of the drug.

                                                Intercept Starts OCA Trial for NASH Patients With Cirrhosis

                                                Intercept (ICPT) initiates a randomized phase III trial, REVERSE, on obeticholic acid in subjects with compensated cirrhosis due to non-alcoholic steatohepatitis.

                                                  Glaxo's (GSK) Begins Phase III HIV Two-Drug Regimen Study

                                                  Glaxo's (GSK) ViiV Healthcare commences phase III study on combo regimen of dolutegravir and lamivudine for maintenance of viral suppression in HIV-1 infection patients treated with TAF-based regimen.